Biomarker detection from urinary EVs is capable of distinguishing aggressive from clinically insignificant PCa and other benign conditions beyond serum PSA and, thus, it might avoid PCa related over-diagnosis and over-treatment. The gene discussed is KLK3; the disease is posterior cortical atrophy.